Is IMVT or INBX more undervalued in 2026?

CirclFi compares Immunovant, Inc. (IMVT) and Inhibrx Biosciences, Inc. (INBX) using 13 institutional-grade valuation models. IMVT has a Quality of Company score of 4.3/10 while INBX scores 5.3/10.

Which is a better buy — IMVT or INBX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IMVT and INBX valuations compare?

IMVT at $33.50 and INBX at $103.98 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IMVT vs INBX Valuation Comparison 2026 — Intrinsic Value Analysis

IMVT

Biotechnology

Immunovant, Inc.

Quality

4.3

out of 10

Value Trap

—

Price

$33.50

Last close

Models

10/13

Active

INBX

Biotechnology

Inhibrx Biosciences, Inc.

Quality

5.3

out of 10

Value Trap

SAFE

Price

$103.98

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	IMVT Fair Value	IMVT Upside	INBX Fair Value	INBX Upside
Bayesian DCF	Intrinsic	$12.58	-62.4%	$28.69	-72.4%
Earnings Power Value	Intrinsic	$17.01	-40.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$6.76	-79.8%	$2.89	-97.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMVT vs INBX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMVT vs INBX — Which Stock Is More Undervalued?

INBX scores higher with a 5.3/10 quality rating vs IMVT's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Immunovant, Inc. (IMVT) and Inhibrx Biosciences, Inc. (INBX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMVT currently trades at $33.50 with a QOC of 4.3/10, while INBX trades at $103.98 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).